Alberto Hernando-Calvo: Durvalumab with Olaparib or Cediranib in patients with pMMR CRC or Pancreatic Cancer
Alberto Hernando-Calvo, Clinician scientist at Vall d’Hebron Barcelona Hospital, shared on X:
“Phase II, open-label, randomized trial of durvalumab with olaparib or cediranib in patients with proficient mismatch repair (pMMR) Colorectal Cancer (CRC) or pancreatic cancer at Princess Margaret Cancer Centre. Mentorship from Aaron Hansen and Lillian Siu and support from Pugh Lab, Benjamin Haibe-Kains labs, Ontario Institute for Cancer Research and others!”
Authors: Alberto Hernando-Calvo, Ming Han, Olubukola Ayodele, Ben X. Wang, Jeffrey P. Bruce, Farnoosh Abbas-Aghababazadeh, Maria Vila-Casadesús, Enrique Sanz-Garcia, S.Y. Cindy Yang, Hal K. Berman, Ana Vivancos, Bernard Lam, Ilinca Lungu, Abdulazeez Salawu, Lee-Anne Stayner, Benjamin Haibe-Kains, Philippe L. Bedard, Lisa Avery, Albiruni R.A. Razak, Trevor J. Pugh, Anna Spreafico, Lillian L. Siu, Aaron R. Hansen.
Source: Alberto Hernando-Calvo/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023